Free Trial

Genmab A/S (GMAB) News Today

→ Elon Musk’s Final Masterpiece: “X-9840” (From Paradigm Press) (Ad)
Free GMAB Stock Alerts
$27.77
-0.78 (-2.73%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends
June 7 at 7:19 AM | marketbeat.com
Capital International Investors Reduces Position in Genmab A/S (NASDAQ:GMAB)
Capital International Investors trimmed its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 6.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,057,922 shares of the company's stock after selling 2
June 6 at 3:42 AM | americanbankingnews.com
Genmab A/S (NASDAQ:GMAB) Price Target Raised to $53.00
June 5 at 12:51 PM | globenewswire.com
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024 | americanbankingnews.com
Genmab A/S (NASDAQ:GMAB) Given "Buy" Rating at HC Wainwright
June 3, 2024 | marketbeat.com
Genmab A/S (NASDAQ:GMAB) Sees Large Growth in Short Interest
Genmab A/S (NASDAQ:GMAB - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 2,960,000 shares, an increase of 7.6% from the April 30th total of 2,750,000 shares. Based on an average daily volume of 520,800 shares, the days-to-cover ratio is presently 5.7 days. Currently, 0.5% of the company's shares are sold short.
June 3, 2024 | marketbeat.com
Campbell & CO Investment Adviser LLC Invests $1.88 Million in Genmab A/S (NASDAQ:GMAB)
Campbell & CO Investment Adviser LLC bought a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 59,003 shares of the company's stock, valued at approxima
June 3, 2024 | globenewswire.com
Transactions in Connection with Share Buy-back Program
June 3, 2024 | businesswire.com
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
June 3, 2024 | marketbeat.com
Genmab A/S (NASDAQ:GMAB) Receives Buy Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Monday.
June 3, 2024 | americanbankingnews.com
Genmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Hold" by Analysts
June 2, 2024 | businesswire.com
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
June 1, 2024 | globenewswire.com
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 1, 2024 | marketbeat.com
Genmab A/S (NASDAQ:GMAB) Shares Sold by Wells Fargo & Company MN
Wells Fargo & Company MN trimmed its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 5.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 557,132 shares of the company's stock after selling 32,261 shares during the
May 27, 2024 | globenewswire.com
Transactions in Connection with Share Buy-back Program
May 24, 2024 | marketbeat.com
Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.34
Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.34
May 23, 2024 | finanznachrichten.de
Genmab A/S: Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 | businesswire.com
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 | globenewswire.com
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 | marketbeat.com
Trexquant Investment LP Buys Shares of 153,098 Genmab A/S (NASDAQ:GMAB)
Trexquant Investment LP bought a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 153,098 shares of the company's stock, valued at approximately $4,875,000. Other institu
May 21, 2024 | marketbeat.com
Aigen Investment Management LP Acquires Shares of 35,889 Genmab A/S (NASDAQ:GMAB)
Aigen Investment Management LP bought a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 35,889 shares of the company's stock, valued at appro
May 21, 2024 | businesswire.com
Genmab Completes Acquisition of ProfoundBio
May 21, 2024 | globenewswire.com
Genmab Completes Acquisition of ProfoundBio
May 21, 2024 | globenewswire.com
Transactions in Connection with Share Buy-back Program
May 21, 2024 | marketbeat.com
Simplicity Wealth LLC Makes New Investment in Genmab A/S (NASDAQ:GMAB)
Simplicity Wealth LLC acquired a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,235 shares of the company's stock, val
May 20, 2024 | investorplace.com
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024 | marketbeat.com
Genmab A/S (NASDAQ:GMAB) Rating Reiterated by HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Monday.
May 15, 2024 | finance.yahoo.com
Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
May 14, 2024 | businesswire.com
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
May 13, 2024 | globenewswire.com
Transactions in Connection with Share Buy-back Program
May 11, 2024 | marketbeat.com
Genmab A/S (NASDAQ:GMAB) Shares Sold by Natixis Advisors L.P.
Natixis Advisors L.P. reduced its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 18.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 187,798 shares of the company's stock aft
May 7, 2024 | globenewswire.com
Capital Increase in Genmab as a Result of Employee Warrant Exercise
May 3, 2024 | markets.businessinsider.com
Optimistic Outlook for Genmab: Strategic Growth and Product Performance Underpin Buy Rating
May 3, 2024 | finance.yahoo.com
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
May 2, 2024 | seekingalpha.com
Genmab A/S 2024 Q1 - Results - Earnings Call Presentation
May 2, 2024 | globenewswire.com
Genmab Announces Financial Results for the First Quarter of 2024
May 1, 2024 | seekingalpha.com
Genmab: A Complicated Tale
April 30, 2024 | marketbeat.com
Short Interest in Genmab A/S (NASDAQ:GMAB) Grows By 9.6%
Genmab A/S (NASDAQ:GMAB - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,630,000 shares, an increase of 9.6% from the March 31st total of 2,400,000 shares. Based on an average trading volume of 575,800 shares, the days-to-cover ratio is presently 4.6 days. Approximately 0.4% of the shares of the company are short sold.
April 30, 2024 | marketbeat.com
HC Wainwright Reaffirms Buy Rating for Genmab A/S (NASDAQ:GMAB)
HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a report on Tuesday.
April 30, 2024 | msn.com
Pfizer, Genmab cervical cancer therapy wins full FDA approval
April 29, 2024 | businesswire.com
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024 | businesswire.com
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024 | globenewswire.com
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024 | globenewswire.com
Transactions in Connection with Share Buy-back Program Genmab
April 22, 2024 | globenewswire.com
Transactions in Connection with Share Buy-back Program Genmab
April 20, 2024 | finance.yahoo.com
Genmab A/S (GMAB)
April 20, 2024 | marketbeat.com
Cerity Partners LLC Acquires 42,661 Shares of Genmab A/S (NASDAQ:GMAB)
Cerity Partners LLC grew its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 344.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,053 shares of the company's stock after purchasin
April 19, 2024 | marketbeat.com
Genmab A/S (NASDAQ:GMAB) to Post FY2024 Earnings of $0.88 Per Share, William Blair Forecasts
Genmab A/S (NASDAQ:GMAB - Free Report) - William Blair dropped their FY2024 earnings per share estimates for Genmab A/S in a note issued to investors on Wednesday, April 17th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of $0.88 for the year, down
April 17, 2024 | marketbeat.com
Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.43
Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.43
April 16, 2024 | finanznachrichten.de
Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2024
April 16, 2024 | globenewswire.com
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
Get Genmab A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.

The new masters of energy (Ad)

According to one source, this new grid could soon provide energy to “one billion people in the world who don’t have access to electricity right now.” And early investors could make a fortune.

Click here to get all the details.

GMAB Media Mentions By Week

GMAB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GMAB
News Sentiment
▼
0.70

0.75
▲
Average
Medical
News Sentiment

GMAB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GMAB Articles
This Week
▼
13

4
▲
GMAB Articles
Average Week

Get Genmab A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:GMAB) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...
Colonial Metals | Sponsored
Urgent alert: open this for a huge profit potential
This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...
Timothy Sykes | Sponsored
Gold Set to EXPLODE!
The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...
Gold Safe Exchange | Sponsored
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Are You Positioned For The New Energy Goldrush?
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored